About this Research Topic
Pulmonary arterial hypertension (PAH) is a complex and diverse group of diseases characterized by a sustained increase in pulmonary arterial pressure. The pathophysiological mechanisms underlying pulmonary arterial hypertension are multifaceted, involving the proliferation of pulmonary arterial smooth muscle cells, thickening, fibrosis and contraction of the pulmonary vessel wall, as well as endothelial dysfunction. This disease involves multiple systems, including the pulmonary circulation, heart, lungs, and peripheral vessels. Recent research has shed light on new pathological and physiological mechanisms related to the adverse prognosis of pulmonary arterial hypertension and right heart failure. For instance, iron deficiency unrelated to anemia, metabolic abnormalities in various cells including pulmonary immune cells like macrophages, and new genetic mutations. Meanwhile, some studies on heart failure with preserved ejection fraction have provided new insights into understanding how left heart disease causes pulmonary arterial hypertension.
Despite ongoing research, pulmonary arterial hypertension remains a significant therapeutic challenge. In this research theme, we invite researchers to provide original research or review articles to help explore new factors that contribute to the pathophysiological mechanisms of pulmonary arterial hypertension, and efforts to design and develop new therapeutic opportunities and strategies. Contributions on Group II or III PAH are particularly encouraged.
Subtopics include, but are not limited to:
· The role of metabolic, autophagy, epigenetics, inflammation, fibrosis, etc.in the pathophysiology of PAH.
· Signaling pathways involved in the onset and development of PAH.
· The field in therapeutic strategies to impede or decelerate the progression of PAH.
We strongly encourage research using animal models and human participants, and studies that include hemodynamic data as well as fundamental measures of cell and organ system biology.
Despite ongoing research, pulmonary arterial hypertension remains a significant therapeutic challenge. In this research theme, we invite researchers to provide original research or review articles to help explore new factors that contribute to the pathophysiological mechanisms of pulmonary arterial hypertension, and efforts to design and develop new therapeutic opportunities and strategies. Contributions on Group II or III PAH are particularly encouraged.
Subtopics include, but are not limited to:
· The role of metabolic, autophagy, epigenetics, inflammation, fibrosis, etc.in the pathophysiology of PAH.
· Signaling pathways involved in the onset and development of PAH.
· The field in therapeutic strategies to impede or decelerate the progression of PAH.
We strongly encourage research using animal models and human participants, and studies that include hemodynamic data as well as fundamental measures of cell and organ system biology.
Keywords: Pulmonary diseases, pulmonary hypertension, pathophysiology, pathogenesis, diagnosis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
